[et_pb_section bb_built=”1″ fullwidth=”on” _builder_version=”3.0.75″ custom_padding=”0px|0px|0px|0px”][et_pb_fullwidth_post_title author=”off” featured_placement=”background” text_color=”light” _builder_version=”3.0.76″ title_font=”|on|||” title_font_size=”33px” title_line_height=”1.3em” meta_font_size=”18px” use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,0,0,0.74)” background_color_gradient_end=”#ffffff” background_color_gradient_direction=”1deg” background_blend=”multiply” custom_padding=”400px||80px|” custom_css_main_element=”border-style: solid;||border-width: 8px 0px 0px 0px;” title=”on” meta=”on” date=”on” categories=”on” comments=”on” featured_image=”on” text_background=”off” border_style=”solid” custom_padding_tablet=”200px||80px|” custom_padding_last_edited=”on|phone” /][/et_pb_section][et_pb_section bb_built=”1″][et_pb_row][et_pb_column type=”4_4″][et_pb_text]
2016 Global Ibogaine Conference
Re-defining Ibogaine’s place in the current drug policy environment
Tepoztlan, Morelos, Mexico
Between March 14-16th, 2016 in Tepoztlan, Mexico, the 2016 Global Ibogaine Conference will convene experts from around the world to discuss ibogaine therapy, the climate of global drug policy, and the sustainability and traditional uses of Tabernanthe iboga.
Since the 1980s ibogaine, the primary psychoactive extract of T. iboga, has increasingly been used experimentally in the detoxification from opiates and as a treatment for substance use disorders. Early clinical trials confirmed some very promising initial reports, but were later suspended because of funding and litigation. Ibogaine’s use has continued to grow, from the early peer-to-peer drug user networks, to today when ibogaine is administered under compassionate access or experimental legal frameworks in some progressive hospitals, medical centers, retreats, and private therapeutic practices around the world.
The landscape of ibogaine research and practice has changed dramatically. However, ibogaine’s continued promotion as a ‘cure for addiction’ overemphasizes it’s potential as a stand-alone therapy while contemporary understandings of addictions address a complex biological, psychological and social foundations of addictive behavior. This conference will bring refreshing voices from across the spectrum of traditional practice, medicine, psychology, harm reduction and drug policy in order to advance the use of ibogaine in a comprehensive therapeutic framework.
The event is a partnership between The Global Ibogaine Therapy Alliance (GITA), the International Center for Ethnobotanical Education, Research & Service (ICEERS), and Espolea (Mexico City). It is the 5th international conference hosted by GITA, and the first major public conference in the series. It features influential speakers from across the fields of psychology, harm reduction, and drug policy reform, and ibogaine research, including Claudio Naranjo, Stanton Peele, Kenneth Alper, Jeffrey Kamlet, Andrew Tatarski, and many others.
The conference pre-session from March 12-13th, 2016 will be the first ever Advanced Cardiac Life Support (ACLS) Certification for ibogaine therapists. The course, available through GITA, goes beyond the standards emergency protocols certified by the American Heart Association to discuss practical concerns for monitoring patients in a clinical setting. It will also include important changes to ACLS interventions and appropriate medications to avoid negative interaction, in order to prevent emergency situations during ibogaine administration.
More information, and registration for the even as well as the pre- and post-conference sessions, can be found on the conference website: http://www.ibogaineconference.org
You can also follow updates on the conference Facebook page:
The Global Ibogaine Therapy Alliance (GITA)
USA: +1 (415) 830-3973
MEX: +52 1 (777) 109-6757